Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term THERAPY. Found 43 abstracts

no pagination
Bagshaw H, Ruth K, Horwitz EM, Chen DY, Buyyounouski MK. Does family history of prostate cancer affect outcomes following radiotherapy?. Radiotherapy and Oncology. 2014 Feb;110(2):229-34.   PMCID: 3991234
Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Kane CJ, Kawachi MH, Kuettel M, Kuzel TM, Lee RJ, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Raben D, Richey S, Roach M, Rohren E, Rosenfeld S, Schaeffer E, Small EJ, Sonpavde G, Srinivas S, Stein C, Strope SA, Tward J, Shead DA, Ho M. Prostate Cancer, Version 2.2014. Journal of the National Comprehensive Cancer Network. 2014 May;12(5):686-718.   PMCID: No NIH funding
Eisenberg BL, Harris J, Blanke CD, Demetri GD, Heinrich MC, Watson JC, Hoffman JP, Okuno S, Kane JM, von Mehren M. Phase II Trial of Neoadjuvant/Adjuvant Imatinib Mesylate (IM) for Advanced Primary and Metastatic/Recurrent Operable Gastrointestinal Stromal Tumor (GIST): Early Results of RTOG 0132/ACRIN 6665. Journal of surgical oncology. 2009 Jan;99(1):42-7.   PMCID: PMC2606912
Fourkal E, Veltchev I, Ma CM. Laser-to-proton energy transfer efficiency in laser-plasma interactions. Journal of Plasma Physics. 2009 Apr;75:235-50.
Karp DD, Paz-Ares LG, Novello S, Haluska P, Garland L, Cardenal F, Blakely LJ, Eisenberg PD, Langer CJ, Blumenschein G, Johnson FM, Green S, Gualberto A. Phase II Study of the Anti-Insulin-Like Growth Factor Type 1 Receptor Antibody CP-751,871 in Combination With Paclitaxel and Carboplatin in Previously Untreated, Locally Advanced, or Metastatic Non-Small-Cell Lung Cancer. Journal of Clinical Oncology. 2009 May;27(15):2516-22.   PMCID: not NIH funded
Kim HJ, Barsevick AM, Tulman L. Predictors of the Intensity of Symptoms in a Cluster in Patients With Breast Cancer. Journal of Nursing Scholarship. 2009 Jan;41(2):158-65.   PMCID: PMC2884278
Lawton CA, Michalski J, El-Naqa I, Buyyounouski MK, Lee WR, Menard C, O'Meara E, Rosenthal SA, Ritter M, Seider M. RTOG GU RADIATION ONCOLOGY SPECIALISTS REACH CONSENSUS ON PELVIC LYMPH NODE VOLUMES FOR HIGH-RISK PROSTATE CANCER. International Journal of Radiation Oncology Biology Physics. 2009 Jun;74(2):383-7.   PMCID: PMC2905150
Lynch HT, Casey MJ, Snyder CL, Bewtra C, Lynch JF, Butts M, Godwin AK. Hereditary ovarian carcinoma: Heterogeneity, molecular genetics, pathology, and management. Molecular Oncology. 2009 Apr;3(2):97-137.   PMCID: PMC2778287
Mason WS, Xu CX, Low HC, Saputelli J, Aldrich CE, Scougall C, Grosse A, Colonno R, Litwin S, Jilbert AR. The Amount of Hepatocyte Turnover That Occurred during Resolution of Transient Hepadnavirus Infections Was Lower When Virus Replication Was Inhibited with Entecavir. Journal of Virology. 2009 Feb;83(4):1778-89.   PMCID: PMC2643773
Oostendorp RL, Loftiss J, Goel S, Smith DA, Dar MM, Witteveen PO, Cohen RB, Lewis LD, Kurian S, Patnaik A, Rosing H, Beijnen JH, Voest EE, Burris H, Schellens JH. Bioequivalence study of a new oral topotecan formulation, relative to the current topotecan formulation, in patients with advanced solid tumors. International Journal of Clinical Pharmacology and Therapeutics. 2009 Mar;47(3):195-206.   PMCID: not NIH funded
Stathakis S, Roland T, Papanikolaou N, Li JS, Ma C. A Prediction Study on Radiation-induced Second Malignancies for IMRT Treatment Delivery. Technology in Cancer Research & Treatment. 2009 Apr;8(2):141-7.
Waldman SA, Hyslop T, Schulz S, Barkun A, Nielsen K, Haaf J, Bonaccorso C, Li YY, Weinberg DS. Association of GUCY2C Expression in Lymph Nodes With Time to Recurrence and Disease-Free Survival in pN0 Colorectal Cancer. JAMA-Journal of the American Medical Association. 2009 Feb;301(7):745-52.   PMCID: PMC 2756012
Donate F, Parry GC, Shaked Y, Hensley H, Guan X, Beck I, Tel-Tsur Z, Plunkett ML, Manuia M, Shaw DE, Kerbel RS, Mazar AP. Pharmacology of the novel antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2): Observation of a U-shaped dose-response curve in several preclinical models of angiogenesis and tumor growth. Clinical Cancer Research. 2008 Apr;14(7):2137-44.
Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, Smith MR. Cardiovascular Mortality and Duration of Androgen Deprivation for Locally Advanced Prostate Cancer: Analysis of RTOG 92-02. European Urology. 2008 Oct;54(4):816-24.
Freeman DJ, Juan T, Reiner M, Hecht JR, Meropol NJ, Berlin J, Mitchell E, Sarosi I, Radinsky R, Amado RG. Association of k-ras mutational status and clinical outcomes in patients with metastatic colorectal. cancer receiving panitumumab alone. Clinical Colorectal Cancer. 2008 May;7(3):184-90.
Hassett MJ, Hughes ME, Niland JC, Edge SB, Theriault RL, Wong YN, Wilson J, Carter WB, Blayney DW, Weeks JC. Chemotherapy Use for Hormone Receptor-Positive, Lymph Node-Negative Breast Cancer. Journal of Clinical Oncology. 2008 Dec;26(34):5553-60.
Hassett MJ, Hughes ME, Niland JC, Ottesen R, Edge SB, Bookman MA, Carlson RW, Theriault RL, Weeks JC. Selecting high priority quality measures for breast cancer quality improvement. Medical Care. 2008 Aug;46(8):762-70.
Marks DI, Perez WS, He W, Zhang MJ, Bishop MR, Bolwell BJ, Bredeson CN, Copelan EA, Gale RP, Gupta V, Hale GA, Isola LM, Jakubowski AA, Keating A, Klumpp TR, Lazarus HM, Liesveld JL, Maziarz RT, McCarthy PL, Sabloff M, Schiller G, Sierra J, Tallman MS, Waller EK, Wiernik PH, Weisdorf DJ. Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission. Blood. 2008 Jul;112(2):426-34.
Pro B, Leber B, Smith M, Fayad L, Romaguera J, Hagemeister F, Rodriguez A, McLaughlin P, Samaniego F, Zwiebel J, Lopez A, Kwak L, Younes A. Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma. British Journal of Haematology. 2008 Nov;143(3):355-60.
Williams SG, Buyyounouski MK, Pickles T, Kestin L, Martinez A, Hanlon AL, Duchesne GM. Percentage of biopsy cores positive for malignancy and biochemical failure following prostate cancer radiotherapy in 3,264 men: Statistical significance without predictive performance. International Journal of Radiation Oncology Biology Physics. 2008 Mar;70(4):1169-75.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term THERAPY

THERAPY TRIAL RADIOTHERAPY SURVIVAL Prostate cancer ADJUVANT CHEMOTHERAPY IMRT ANDROGEN DEPRIVATION LUNG-CANCER Oncology SOLID TUMORS EXTERNAL-BEAM RADIOTHERAPY EXTERNAL-BEAM RADIATION WOMEN CARCINOMA predictors oral formulation topotecan-bioequivalence-food-effect locally advanced GIST Monte Carlo ALLOGENEIC TRANSPLANTATION EXPERIMENTAL monoclonal antibodies GENE-EXPRESSION RISK REDUCING RESECTION Gonadotropin-releasing hormone agonist clinical practice guidelines ESCALATION NONPOLYPOSIS COLORECTAL-CANCER INTRAVENOUS TOPOTECAN Nuclear Medicine & Medical Imaging Radiology Symptom clusters DEPRIVATION OF-CARE HORMONE AGONISTS IMMEDIATE HIGHLIGHTS LEIOMYOSARCOMAS DOSE-RESPONSE RESISTANCE OPEN-LABEL CETUXIMAB biochemical failure SALPINGO-OOPHORECTOMY RADICAL HODGKINS-DISEASE prognostic models Radiation FAILURE PLUS MEN ANTIGEN 3-DIMENSIONAL CONFORMAL PAY-FOR-PERFORMANCE IMPACT DISEASE SURGERY Hereditary ovarian cancer NEOADJUVANT HEALTH-CARE COLITIS RECURRENCE PHASE-III PREDICT RECURRENCE ACCELERATION IMATINIB CHEMOTHERAPY-NAIVE PATIENTS CHEMOTHERAPY PROSTATE-CANCER Second malignancy TOPOISOMERASE-I IGF breast cancer and medical intervention oncology guidelines FATIGUE MESSENGER-RNA CLINICAL TARGET VOLUME DNA-MISMATCH-REPAIR Hereditary recurrent B-cell NHL treatment VIABILITY MICROMETASTASES STEREOTACTIC BODY RADIOTHERAPY RELATIVISTIC IONS CYCLOPHOSPHAMIDE WOODCHUCKS symptom management DIAGNOSIS SURGICAL-MANAGEMENT ORGANIZATIONS TAMOXIFEN Family history Pelvic lymph nodes Ovarian cancer neoadjuvant imatinib PROTEIN EXPRESSION ENDOTHELIAL-CELLS 3D-CRT INTEGRIN ALPHA(5)BETA(1) symptom assessment IONIZING-RADIATION ENDOSTATIN prostate cancer Review IRRADIATION CELL LUNG-CANCER GUANYLYL CYCLASE-C non-Hodgkin lymphoma PHASE-III TRIAL FALLOPIAN-TUBE CARCINOMA PROGNOSTIC-SIGNIFICANCE BODY-COMPOSITION Conventional radiotherapy INHIBITION ADULT PATIENTS GUIDELINES LIVER NCCN COLLIMATED BEAMS CLINICAL UTILITY INDICATORS DOSE-RATE BRACHYTHERAPY PROGNOSTIC MODELS TYROSINE breast cancer CONSENSUS PROGNOSIS breast-ovarian cancer syndrome oblimersen sodium SEROUS PAPILLARY CARCINOMA GENERATION metastatic GIST CLEARANCE Hormonal therapy STRAND DNA EFFICACY STATISTICS RADICAL PROSTATECTOMY SUPPRESSION PLASMA-LEVELS BRCA2 MUTATION CARRIERS HORMONE REPLACEMENT QUALITY-OF-LIFE BIOAVAILABILITY Radiotherapy Radiation therapy Lynch syndrome KRAS MUTATION
Last updated on Thursday, April 02, 2020